C o
n t e n t s1
7 5EditorialJean-Paul Macher, Marc-Antoine
CrocqClinical
psychopharmacologyPsychotropic
medication, psychiatric disorders, and
higher brain functionsPierre
Schulz, Thierry SteimerThe
value of assessing cognitive function in
drug developmentKeith
A. WesnesDesigning
and interpreting the results of
first-time-to-man studiesAlain
A. PatatFDA
relations during drug developmentJules
T. MitchelCerebral
aging and Alzheimer’s diseaseNMDA
receptor function, memory,and
brain agingJohn
W. Newcomer, Nuri B. Farber, John W. OlneyInflammation and the pathophysiology
of Alzheimer’s
diseaseGreer
M. Murphy JrEarly
diagnosis of Alzheimer’s disease: update on
combining genetic and brain-imaging measuresGary
W. SmallPharmacological
models in Alzheimer’s disease
researchChristian
Gilles, Stéphane ErtléSchizophreniaSchizophrenia: vulnerability versus
diseaseMing T. Tsuang, William
S. Stone, Stephen V. FaraoneNeural
models of schizophreniaStephan
Heckers
Vol 2 n° 3 - From Research
to Treatment in Clinical Neuroscience
Alert